Health Technology
Takeda Pharmaceutical Co., Ltd.
- 3,753.00 JPY
- +3.00
- +0.08%
Japan
Jun 14, 2019Ticker
TKS(4502)Prev. close
3,750Market cap (JPY)
5,911.34BMarket cap (USD)
54,630.90MShares
1,576.36M
In the news
- Japan's record economic growth faces shaky outlook May 29, 2019
- Drugmaker Takeda to introduce value-based pricing in Europe Apr 29, 2019
- Japan's lopsided M&A boom Mar 4, 2019
- Takeda and rivals chase cancer therapy prize through M&A Jan 8, 2019
- Japan's MUFG extends $18bn loan to Bristol-Myers for megadeal Jan 5, 2019 See more articles on Takeda Pharmaceutical Co., Ltd.
Business Summary
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.
Financial Highlights
| Mar 2019 | JPY | USD |
| Revenue | 2,097.22B | 18,911.85M |
| Gross Profit | 1,234.16B | 11,129.13M |
| Operating income | 172,782M | 1,558.07M |
| Income before tax | 94,896M | 855.73M |
| Net income | 109,126M | 984.05M |
| EBITDA | 445,228M | 4,014.87M |
| Diluted EPS | 112.86 | 1.01 |
| Dividends Per Share | 180 | 1.62 |
| Total Assets | 13,872.32B | 125,331.55M |
| Total liabilities | 8,708.73B | 78,680.35M |
| Total equity | 5,159.58B | 46,615.00M |
| Operating cash flow | 302,609M | 2,728.79M |
| Currency in JPY | Currency in USD |
Historical Data
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | |
| Revenue | 1,777.82B | 1,807.37B | 1,732.05B | 1,770.53B | 2,097.22B |
| Gross Profit | 1,134.39B | 1,161.84B | 1,017.65B | 1,148.86B | 1,234.16B |
| Operating income | 195,804M | 175,770M | 86,972M | 195,320M | 172,782M |
| Income before tax | -145,437M | 120,539M | 143,346M | 217,205M | 94,896M |
| Net income | -145,775M | 80,166M | 114,940M | 186,886M | 109,126M |
| EBITDA | 387,391M | 353,275M | 258,398M | 377,447M | 445,228M |
| Diluted EPS | -185.37 | 101.71 | 146.25 | 237.55 | 112.86 |
| Dividends Per Share | 180 | 180 | 180 | 180 | 180 |
| Total Assets | 4,296.19B | 3,824.08B | 4,346.79B | 4,106.46B | 13,872.32B |
| Total liabilities | 2,090.01B | 1,812.88B | 2,397.82B | 2,089.05B | 8,708.73B |
| Total equity | 2,137.04B | 1,948.69B | 1,894.26B | 1,997.42B | 5,159.58B |
| Operating cash flow | 183,441M | 26,552M | 260,067M | 379,600M | 302,609M |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | |
| Revenue | 16,183.14M | 15,050.91M | 15,994.93M | 15,974.84M | 18,911.85M |
| Gross Profit | 10,326.11M | 9,675.22M | 9,397.74M | 10,365.80M | 11,129.13M |
| Operating income | 1,782.36M | 1,463.72M | 803.15M | 1,762.30M | 1,558.07M |
| Income before tax | -1,323.88M | 1,003.78M | 1,323.75M | 1,959.76M | 855.73M |
| Net income | -1,326.95M | 667.58M | 1,061.43M | 1,686.20M | 984.05M |
| EBITDA | 3,526.33M | 2,941.89M | 2,386.22M | 3,405.56M | 4,014.87M |
| Diluted EPS | -1.68 | 0.84 | 1.35 | 2.14 | 1.01 |
| Dividends Per Share | 1.63 | 1.49 | 1.66 | 1.62 | 1.62 |
| Total Assets | 35,823.98M | 34,023.62M | 39,009.18M | 38,612.71M | 125,331.55M |
| Total liabilities | 17,427.69M | 16,129.56M | 21,518.70M | 19,643.19M | 78,680.35M |
| Total equity | 17,819.86M | 17,337.88M | 16,999.56M | 18,781.60M | 46,615.00M |
| Operating cash flow | 1,669.82M | 221.11M | 2,401.63M | 3,424.99M | 2,728.79M |
Valuation Measures
| Mar 2019 | |
| PER | 39.83 |
| ROA | 1.21% |
| ROE | 3.04% |
| Operating margin | 8.23% |
| Profit margin | 5.20% |
Key executives
- President, CEO & Representative Director: Christophe Weber
- Chief Financial Officer: Costa Saroukos
- Director, Chief Medical & Scientific Officer: Andrew S. Plump
- Executive Officer & Global General Counsel: Yoshihiro Nakagawa
- Global Human Resources Officer & Executive Officer: David Osborne
Shareholders
- Sumitomo Mitsui Trust Asset Management Co., Ltd. (3.4%)
- BlackRock Fund Advisors (3.1%)
- Asset Management One Co., Ltd. (2.7%)
- Causeway Capital Management LLC (2.6%)
- Nippon Life Insurance Co. (2.6%)
- The Vanguard Group, Inc. (1.9%)
- Capital Research & Management Co. (World Investors) (1.7%)
- Nomura Asset Management Co., Ltd. (1.6%)
- Nikko Asset Management Co., Ltd. (1.6%)
- State Street Global Advisors Ltd. (1.5%)
Contact Details
- Website:http://www.takeda.co.jp
- Address: 4-1-1 Dosho-machi, Chuo-Ku, Osaka, 540-8645, Japan
- Phone: +81.6.6204.2111
Related Companies
- Takeda Re Insurance AG
- Takeda Pharmaceutical Co. Ltd. /Tachosil Business/
- Takeda Pharmaceutical Co. Ltd. /Xiidra Business/
- Plasmapunkt Favoriten GmbH
- Takeda Malaysia Sdn. Bhd.
- Takeda Pharmaceutical Co. Ltd. /Latam Bus/
- Takeda Oranienburg Real Estate GmbH & Co. KG
- Takeda Consumer Healthcare Co. Ltd.
- Takeda Pharmaceutical Director Incentive Plan
- Takeda Pharmaceutical Employee Incentive Plan
- Oy Leiras Takeda Pharmaceuticals AB
- Takeda Architectural Design Consulting (Shanghai) Co. Ltd.
- Takeda Pharma AB
- Takeda Development Center Americas, Inc.
- Takeda Ukraine LLC
- Takeda Pharmaceuticals Taiwan Ltd.
- Takeda SRL
- Takeda Hellas SA
- Takeda Christiaens SCA/CVA
- Takeda Belgium SCA/CVA
- Takeda Vaccines Pte Ltd.
- Takeda Pharmaceuticals (Asia Pacific) Pte Ltd.
- Takeda Development Center Asia Pte Ltd.
- Takeda Pharma Sp zoo
- Takeda Mexico SA de CV
- Takeda Kazakhstan LLP
- Takeda Pharmaceuticals Korea Co., Ltd.
- Takeda Farmaceutica Espana SA
- Takeda Pharma Ltda.
- Takeda Distribuidora Ltda.
Competitors
- Dr. Reddy's Laboratories Ltd.
- Sanofi
- AstraZeneca PLC
- Ipsen SA
- Amgen Inc.
- Eli Lilly and Company
- Daewoong Co., Ltd.
- Hanmi Pharmaceutical Co., Ltd.
- Grifols, S.A. Class A
- MorphoSys AG
- Hypera S.A.
- Celgene Corporation
- JSC Kyivmedpreparat
- YungShin Global Holding Corp.
- Endo International Plc
- Assembly Biosciences, Inc.
- Gossamer Bio, Inc.
- Moderna, Inc.
- Hanall Biopharma Co., Ltd.
- Hutchison China MediTech Limited
- RedHill Biopharma Ltd.
- Nektar Therapeutics
- Chimerix, Inc.
- Ironwood Pharmaceuticals, Inc. Class A
- Sangamo Therapeutics, Inc.
- Spectrum Pharmaceuticals, Inc.
- Galapagos NV
- Denali Therapeutics Inc.
- uniQure N.V.
- Reata Pharmaceuticals, Inc. Class A
Copyright © 2019 FactSet Research Systems Inc. All rights reserved.
Last Updated on 14 Jun, 2019